GW Pharmaceuticals PLC Result of AGM (1066T)
March 23 2016 - 12:07PM
UK Regulatory
TIDMGWP
RNS Number : 1066T
GW Pharmaceuticals PLC
23 March 2016
GW Pharmaceuticals Announces Results of Annual General
Meeting
Cambridge, UK, 23 March 2016: GW Pharmaceuticals plc (AIM: GWP,
NASDAQ: GWPH or the "Company") hereby provides notification that,
at the Annual General Meeting of the Company held earlier today,
all the resolutions set out in the Notice of Meeting sent to
shareholders were duly proposed and passed.
All resolutions were approved on a show of hands. Details of the
proxy votes received in relation to each of the resolutions (which
are more particularly described in the Notice of General Meeting)
are as follows:
For(1, 2) Against(1) Withheld
--------------------------- --------------------- -------------------- ----------
Ordinary resolutions
------------------------------------------------------------------------ ----------
Resolution 1 - To
receive, consider
and adopt the Directors'
and Auditors' Reports
and Statement of
Accounts for the
year ended 30 September
2016 224,039,382 99.80% 450,875 0.20% 285,420
--------------------------- ------------ ------- ----------- ------- ----------
Resolution 2 - To
approve the Directors'
Remuneration Report 220,340,924 98.19% 4,051,711 1.81% 383,042
--------------------------- ------------ ------- ----------- ------- ----------
Resolution 3 - To
re-elect Adam George
as a Director 199,151,339 88.76% 25,229,611 11.24% 394,727
--------------------------- ------------ ------- ----------- ------- ----------
Resolution 4 - To
re-elect James Noble
as a Director 219,904,356 98.00% 4,491,570 2.00% 379,751
--------------------------- ------------ ------- ----------- ------- ----------
Resolution 5 - To
re-elect Christopher
Tovey as a Director 199,224,442 88.78% 25,176,764 11.22% 374,471
--------------------------- ------------ ------- ----------- ------- ----------
Resolution 6 - To
re-elect Julian
Gangolli as a Director 193,476,666 86.22% 30,921,912 13.78% 377,099
--------------------------- ------------ ------- ----------- ------- ----------
Resolution 7 - To
re-appoint Deloitte
LLP as Auditor 224,411,844 99.90% 222,865 0.10% 140,968
--------------------------- ------------ ------- ----------- ------- ----------
Resolution 8 - To
authorise the Directors
to determine the
Auditor's remuneration 224,066,168 99.79% 478,704 0.21% 227,680
--------------------------- ------------ ------- ----------- ------- ----------
Resolution 9 - To
authorize an increase
in the aggregate
annual limit on
the fees payable
to Directors to
GBP1,000,000 222,644,542 99.20% 1,794,438 0.80% 333,570
--------------------------- ------------ ------- ----------- ------- ----------
Special Resolutions (requires 75% majority)
------------------------------------------------------------------------ ----------
Resolution 10 -
That the Directors
be authorised to
disapply pre-emption
rights for cash
issues of up to
20% of the Company's
issued share capital 181,835,330 81.02% 42,586,722 18.98% 353,625
--------------------------- ------------ ------- ----------- ------- ----------
(1) A vote withheld is not a vote in law and, is not counted in
the calculation of the votes for or against a resolution.
Therefore, the percentage of votes cast excludes withheld
votes.
(2) Proxy forms which gave the Chairman or other officer of the
Company discretion have been included in the "For" total.
On 23 March 2016, there were 262,717,686 GW Pharmaceuticals plc
ordinary shares in issue. Shareholders are entitled to one vote per
share held.
The full text of each resolution passed at the Annual General
Meeting held earlier today, Wednesday 23 March 2016, is set out in
the Notice of Annual General Meeting which is available for viewing
on the Company's website at www.gwpharm.com.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform in a broad range of
disease areas. GW commercialized the world's first plant-derived
cannabinoid prescription drug, Sativex(R), which is approved for
the treatment of spasticity due to multiple sclerosis in 28
countries outside the United States. GW is advancing an orphan drug
program in the field of childhood epilepsy with a focus on
Epidiolex(R) (cannabidiol), which is in Phase 3 clinical
development for the treatment of Dravet syndrome and Lennox-Gastaut
syndrome and which is also expected to enter Phase 3 clinical
trials in the treatment of Tuberous Sclerosis Complex. GW has a
deep pipeline of additional cannabinoid product candidates which
includes compounds in Phase 1 and 2 trials for glioma, type 2
diabetes, schizophrenia and epilepsy. For further information,
please visit www.gwpharm.com.
For further information, please contact:
GW Pharmaceuticals plc
Adam George, Company Secretary +44 (0)1980 557 000
Peel Hunt LLP (UK NOMAD)
James Steel +44 20 7418 8900
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGUORBRNVAOUAR
(END) Dow Jones Newswires
March 23, 2016 13:07 ET (17:07 GMT)
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024